Dyskinesia Pipeline Summary

DelveInsight’s, “Dyskinesia - Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dyskinesia: Understanding

Dyskinesia: Overview

Dyskinesia is a movement disorder characterized by involuntary, excessive, and uncontrolled movements that may affect the face, trunk, limbs, or neck. It is most commonly observed as levodopa-induced dyskinesia (LID) in patients with Parkinson's disease receiving long-term dopaminergic therapy, although it may also result from exposure to dopamine receptor-blocking agents (tardive dyskinesia), genetic disorders, or other neurological diseases.

Dyskinetic movements may appear as chorea, dystonia, athetosis, or ballistic movements and can range from mild to severely disabling. Patients often experience writhing, fidgeting, twisting, or jerking movements that interfere with walking, speaking, eating, and daily activities, thereby reducing quality of life. The risk of dyskinesia increases with younger age at Parkinson's disease onset, longer disease duration, higher cumulative levodopa exposure, and greater disease severity.

The pathophysiology of dyskinesia involves abnormal basal ganglia circuitry and maladaptive neuroplasticity resulting from dopaminergic dysfunction. In levodopa-induced dyskinesia, degeneration of nigrostriatal dopaminergic neurons causes intermittent, non-physiological stimulation of dopamine receptors following levodopa administration, leading to alterations in D1 receptor signaling, glutamatergic transmission, serotonergic modulation, and intracellular pathways involving ERK and mTOR. These changes produce abnormal neuronal firing patterns within the basal ganglia-thalamocortical network, resulting in involuntary movements.

Diagnosis is primarily clinical and is based on detailed history, neurological examination, medication review, and characterization of movement patterns, while standardized rating scales such as the Unified Dyskinesia Rating Scale (UDysRS) and video assessment help quantify severity and monitor treatment response. Neuroimaging is generally reserved for excluding alternative neurological disorders.

Treatment of dyskinesia aims to reduce involuntary movements while maintaining optimal motor control. In Parkinson's disease, management includes adjusting levodopa dosing schedules, reducing individual levodopa doses while increasing dosing frequency, and optimizing adjunctive therapies such as dopamine agonists, MAO-B inhibitors, or COMT inhibitors to minimize motor fluctuations. Amantadine, particularly extended-release formulations, remains the only medication with strong evidence for reducing levodopa-induced dyskinesia, while deep brain stimulation (DBS) of the subthalamic nucleus or globus pallidus internus is recommended for carefully selected patients with medically refractory motor complications.

Treatment of tardive dyskinesia includes discontinuation or dose reduction of the offending dopamine receptor-blocking agent when feasible and use of vesicular monoamine transporter 2 (VMAT2) inhibitors, such as valbenazine or deutetrabenazine. Multidisciplinary care, including physical therapy, occupational therapy, speech therapy, and regular neurological follow-up, is essential to optimize long-term functional outcomes.

"Dyskinesia- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dyskinesia pipeline landscape is provided which includes the disease overview and Dyskinesia treatment guidelines. The assessment part of the report embraces, in depth Dyskinesia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Dyskinesia R&D. The therapies under development are focused on novel approaches to treat/improve Dyskinesia.

Dyskinesia Emerging Drugs Chapters

This segment of the Dyskinesia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dyskinesia Emerging Drugs

LY03015: Luye Pharma Group

LY03015 is an investigational, orally administered small-molecule dual-acting vesicular monoamine transporter 2 (VMAT2) inhibitor and sigma-1 receptor (Sigma-1R) agonist being developed for the treatment of tardive dyskinesia. It is designed to reduce excessive presynaptic dopamine release through VMAT2 inhibition while simultaneously activating Sigma-1R to promote synaptic remodeling and neuroprotective pathways, with the potential to provide both symptomatic relief and disease-modifying benefits. Preclinical and early clinical findings suggest that this dual mechanism may result in sustained symptom improvement with minimal rebound after treatment discontinuation. LY03015 has demonstrated positive Phase II results in China, meeting its primary endpoint with a favorable safety and tolerability profile, and is being advanced toward global late-stage development.

DSP-0551: Sumitomo Pharma

DSP-0551 is an investigational oral small-molecule multi-ion channel modulator being developed for the treatment of Parkinson's disease–associated tremor. It was identified through phenotype-based drug discovery and inhibits multiple T-type calcium and sodium ion channels implicated in abnormal neuronal excitability and tremor generation. By modulating aberrant neuronal firing and excessive synchronization within tremor-related neural circuits, DSP-0551 aims to improve motor symptoms while offering a novel non-dopaminergic therapeutic approach. The candidate is currently in Phase I clinical development in Japan to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamic profile.

Further product details are provided in the report……..

Dyskinesia: Therapeutic Assessment

This segment of the report provides insights about the different Dyskinesia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Dyskinesia
• There are approx. 20+ key companies which are developing the therapies for Dyskinesia. The companies which have their Dyskinesia drug candidates in the mid stage, i.e. Phase II include, LY03015.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dyskinesia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Dyskinesia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dyskinesia drugs.

Dyskinesia Report Insights

• Dyskinesia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dyskinesia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dyskinesia drugs?
• How many Dyskinesia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dyskinesia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dyskinesia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dyskinesia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Luye Pharma Group
• Neurocrine Biosciences
• Sumitomo Pharma
• Serina Therapeutics, Inc.
• Neurolixis
• Immunis
• Sinopia Biosciences
• Acadia Pharmaceuticals Inc
• SOM Biotech
• Medicure
• IRLAB Therapeutics
• Vistagen

Key Products

• LY03015
• NBI-1065890
• DSP-0551
• SER-270
• NLX-112
• Nalfurafine
• SB 0110
• ACP?271
• SOM3355
• TARDOXAL
• IRL790
• AV-101